ASTRAZENECA PLC - ANNUAL GENERAL MEETING : 28 APRIL 2011

AstraZeneca PLC announced the results of the voting at its Annual General Meeting today.  As proposed in the Notice of AGM, all Resolutions were decided by poll vote.

Resolution 1: Ordinary Resolution to receive the Company’s Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2010:

VOTES FOR:                    906,283,708 (98.43%)

VOTES AGAINST:           14,422,750 (1.57%)

The Resolution was passed as an Ordinary Resolution.

Resolution 2: Ordinary Resolution to confirm dividends:

VOTES FOR:                    914,481,512 (99.59%)

VOTES AGAINST:           3,777,820 (0.41%)

The Resolution was passed as an Ordinary Resolution.

Resolution 3: Ordinary Resolution to re-appoint KPMG Audit Plc, London as Auditor:

VOTES FOR:                    910,685,868 (99.40%)

VOTES AGAINST:           5,470,026 (0.60%)

The Resolution was passed as an Ordinary Resolution.

Resolution 4: Ordinary Resolution to authorise the Directors to agree the remuneration of the Auditor:

VOTES FOR:                    880,931,217 (96.47%)

VOTES AGAINST:           32,263,466 (3.53%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(a): Ordinary Resolution to re-elect Louis Schweitzer as a Director:

VOTES FOR:                    900,378,537 (98.30%)

VOTES AGAINST:           15,605,396 (1.70%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(b): Ordinary Resolution to re-elect David Brennan as a Director:

VOTES FOR:                    909,890,704 (99.62%)

VOTES AGAINST:           3,463,117 (0.38%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(c): Ordinary Resolution to re-elect Simon Lowth as a Director:

VOTES FOR:                    914,220,800 (99.76%)

VOTES AGAINST:           2,224,743 (0.24%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(d): Ordinary Resolution to elect Bruce Burlington as a Director:

VOTES FOR:                    915,962,963 (99.78%)

VOTES AGAINST:           1,975,916 (0.22%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(e): Ordinary Resolution to re-elect Jean-Philippe Courtois as a Director:

VOTES FOR:                    915,140,939 (99.86%)

VOTES AGAINST:           1,291,497 (0.14%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(f): Ordinary Resolution to re-elect Michele Hooper as a Director:

VOTES FOR:                    890,405,843 (97.00%)

VOTES AGAINST:           27,517,923 (3.00%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(g): Ordinary Resolution to re-elect Rudy Markham as a Director:

VOTES FOR:                    892,872,331 (97.44%)

VOTES AGAINST:           23,490,480 (2.56%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(h): Ordinary Resolution to re-elect Dame Nancy Rothwell as a Director:

VOTES FOR:                    917,144,538 (99.59%)

VOTES AGAINST:           3,791,953 (0.41%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(i): Ordinary Resolution to re-elect Shriti Vadera as a Director:

VOTES FOR:                    919,539,402 (99.85%)

VOTES AGAINST:           1,382,661 (0.15%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(j): Ordinary Resolution to re-elect John Varley as a Director:

VOTES FOR:                    917,033,075 (99.58%)

VOTES AGAINST:           3,879,940 (0.42%)

The Resolution was passed as an Ordinary Resolution.

Resolution 5(k): Ordinary Resolution to re-elect Marcus Wallenberg as a Director:

VOTES FOR:                    735,420,739 (81.43%)

VOTES AGAINST:           167,722,550 (18.57%)

The Resolution was passed as an Ordinary Resolution.

Resolution 6: Ordinary Resolution to approve the Directors’ Remuneration Report for the year ended 31 December 2010:

VOTES FOR:                    864,316,448 (95.43%)

VOTES AGAINST:           41,382,777 (4.57%)

The Resolution was passed as an Ordinary Resolution.

Resolution 7: Ordinary Resolution to authorise limited EU political donations:

VOTES FOR:                    887,903,408 (97.32%)

VOTES AGAINST:           24,472,598 (2.68%)

The Resolution was passed as an Ordinary Resolution.

Resolution 8: Ordinary Resolution to authorise the Directors to allot shares:

VOTES FOR:                    884,978,464 (96.11%)

VOTES AGAINST:           35,838,068 (3.89%)

The Resolution was passed as an Ordinary Resolution.

Resolution 9: Special Resolution to authorise the Directors to disapply pre-emption rights:

VOTES FOR:                    911,674,415 (99.03%)

VOTES AGAINST:           8,892,230 (0.97%)

The Resolution was passed as a Special Resolution.

Resolution 10: Special Resolution to authorise the Company to purchase its own shares:

VOTES FOR:                    884,192,625 (96.82%)

VOTES AGAINST:           29,041,657 (3.18%)

The Resolution was passed as a Special Resolution.

Resolution 11: Special Resolution to reduce the notice period for general meetings:

VOTES FOR:                    819,876,012 (89.12%)

VOTES AGAINST:           100,063,311 (10.88%)

The Resolution was passed as a Special Resolution.

A C N Kemp

Company Secretary

28 April 2011

Taggar:

Om oss

AstraZeneca är ett globalt, innovationsdrivet bioläkemedelsföretag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom tre huvudsakliga terapiområden: cancer, kardiovaskulära sjukdomar, njursjukdomar och metabola sjukdomar och sjukdomar i andningsvägarna. Bolaget är också selektivt aktivt inom autoimmunitet, neurovetenskap och infektion. AstraZeneca bedriver verksamhet i över 100 länder och dess innovativa läkemedel används av miljontals patienter över hela världen. Mer information finns på: www.astrazeneca.com och www.astrazeneca.se

Kontakt

Prenumerera